Population Genetics of Pharmacogenetic Variants in a Greek Psychiatric Cohort of over 3000 Individuals
Open Access
- 11 October 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9896
Abstract
Psychiatric disorders affect nearly one billion people worldwide and remain a major therapeutic challenge due to frequent treatment resistance. Pharmacogenetics provides a precision-informed approach by accounting for interindividual variability in drug metabolism and response, and population-specific data offer valuable information for therapeutic considerations. This study analyzed 3011 Greek individuals to assess 24 pharmacogenetic variants across 13 genes. Genotyping was performed using TaqMan OpenArray® assays, and metabolic phenotypes were predicted based on established genotype-to-phenotype translation guidelines. Allele frequencies were compared with those in European, African, and East Asian populations. Population structure and genetic differentiation were evaluated using Principal Component Analysis (PCA), K-means clustering, fixation index (FST), and STRUCTURE analysis. Results indicated that most allele frequencies in Greeks aligned with those in European populations, while several CYP2D6 and CYP2C19 variants differed significantly from those in African and East Asian cohorts. PCA and clustering confirmed strong European affinity, supported by low FST values, whereas STRUCTURE revealed minimal non-European admixture. Predicted metabolic phenotypes showed that 36%, 57.7%, and 41.6% of individuals exhibited altered CYP2D6, CYP2C19, and CYP2C9 activity, respectively. These findings highlight clinically actionable variation in the Greek population and emphasize the use of population-specific pharmacogenetic data to inform optimized strategies in precision psychiatry.Keywords
This publication has 45 references indexed in Scilit:
- The Genetic Testing Reference Materials Coordination ProgramThe Journal of Molecular Diagnostics, 2023
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor AntidepressantsClinical Pharmacology & Therapeutics, 2023
- Population pharmacogenomics: an update on ethnogeographic differences and opportunities for precision public healthHuman Genetics, 2021
- Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019The Journal of Clinical Pharmacology, 2021
- Recommendations for Clinical CYP2D6 Genotyping Allele SelectionThe Journal of Molecular Diagnostics, 2021
- Worldwide Distribution of Cytochrome P450 Alleles: A Meta‐analysis of Population‐scale Sequencing ProjectsClinical Pharmacology & Therapeutics, 2017
- Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 updateClinical Pharmacology & Therapeutics, 2016
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsClinical Pharmacology & Therapeutics, 2015
- A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology & Therapeutics, 2006
- New Features of Categorical Principal Components Analysis for Complicated Data Sets, Including Data Mining2002